Introduction
The cytokine TNF-like weak inducer of apoptosis (TWEAK) is a member of the TNF superfamily. 1 TWEAK is initially synthesized as a type II transmembrane protein and cleaved to its soluble form. 1, 2 Both membrane-bound and soluble TWEAK proteins are fully functional. Fibroblast growth-factor-inducible 14 (Fn14), a type I transmembrane protein, has been identified as the TWEAK receptor. 3, 4 TWEAK acts as a multifunctional cytokine and it is involved in physiological responses including cell survival, proliferation, angiogenesis, migration, and apoptosis, 2 and also in pathogenesis of different diseases, such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, stroke, neuroinflammation, neurodegeneration, and several types of cancer. [5] [6] [7] [8] TWEAK may also be involved in the pathogenesis of cardiovascular diseases. Jain et al. 9 found that patients with dilated cardiomyopathy have TWEAK levels up-regulated with respect to control subjects, suggesting that TW/Fn14 pathway can regulate cardiomyocyte elongation and cardiac fibrosis. Other authors have also shown that elevated levels of circulating TWEAK via Fn14 affected the cardiac extracellular matrix, increasing fibrosis, and cardiomyocyte hypertrophy in mice. [10] [11] [12] [13] The effect of TWEAK on human endothelial cells has been described by different authors. TWEAK induces the proliferation and migration of endothelial cells, [14] [15] [16] up-regulates the cell surface expression of adhesion molecules such as ICAM-1 or E-selectine, induces the secretion of chemokines such as IL-8 and MCP-1, 15 and induces angiogenesis. 16 Both TWEAK and Fn14 have been detected in human atherosclerotic plaques, suggesting that these molecules may play a role in the atherogenic process. Muñoz-Garc ıa et al. 17 demonstrated that TWEAK administered for 9 days to ApoE-deficient mice promotes an increase in atherosclerotic lesion area by increasing the inflammatory response in the vascular wall. However, Schapira et al. 18 suggested that TWEAK/Fn14 interactions prevent the progression to a more advanced phenotype in ApoE-deficient mice. Both suggest that endogenous TWEAK participates in the atherogenic process, but apparently using different receptors, the known receptor Fn14 and the scavenger receptor CD163. 19 Endothelium exerts multiple functions to preserve vascular homeostasis. Vasoactive endothelial factors such as nitric oxide (NO) or endothelin-1 (ET-1) are involved in this regulation. An unbalanced production of these bioactive mediators results in endothelial dysfunction, a critical event in the development of renal and cardiovascular damage in some diseases like diabetes, hypertension, or atherosclerosis. [20] [21] [22] ET-1, 23 discovered in 1988, is the most powerful vasoconstrictor peptide known. Its synthesis is the result of two main steps. The first one converts the long precursor prepro-ET-1 into the inactive short precursor big ET-1, and the second one converts big ET-1 specifically into ET-1 through the action of the endothelin-converting enzyme-1 (ECE-1). 24 ECE-1 is a zinc type II membrane metallopeptidase protein, 25 an enzyme with four different isoforms generated by alternative splicing. 26 ECE-1 activity has been considered critical for ET-1 synthesis, and it has been demonstrated that the blockade of this protein exerts a beneficial effect on some cardiovascular diseases. 27 For this reason, its regulation has been actively investigated. Reactive oxygen species, 28, 29 oxidized low density lipoproteins, 30 angiotensin II, 31 NO, 32 vitamin D, 33 calcimimetics, 34 and big ET-1 itself 35 may be involved in the regulation of its activity or content. Herein, the present work aimed to analyse the ability of TWEAK to modify the endothelin system, particularly ET-1 and ECE-1, studying the intracellular mechanisms responsible for this modulation. Moreover, the endothelial changes induced by TWEAK were also tested in vivo. Our findings support the up-regulation of ET-1 synthesis by TWEAK through the modulation of ECE-1, with the subsequent changes in local and systemic haemodynamic. In pathological situations such as chronic inflammation, TWEAK could be more harmful through this effect at endothelial level. Pharmacological blockage of this cytokine could be very useful as potential therapeutic target.
Methods
Please see Supplementary material online, Supplementary Data, for detailed methods.
Cell culture
EA.hy926 (EA), a human macrovascular endothelial cell line was from American Type Culture Collection, were grown in Dulbecco's Modified Eagle Media (DMEM) containing 4.5 g/L glucose and supplemented with 10% foetal bovine serum, 100 U/mL penicillin/100 mg/mL streptomycin in an atmosphere of 95% air and 5% CO 2 . Supernatants were collected to measure ET-1 by enzyme-linked immunosorbent assay. 29 
Animal studies
Three-month-old male CD-1 mice were obtained from Harlan Laboratories. Animals were kept on a 12:12-h light-dark cycle, at 24 C, and food and water were available ad libitum. The study design and the experimental protocols were performed in agreement with the Guide for the Care and Use of Laboratory Animals published by the US National Institute of Health (Eighth Edition, 2011) and with the European Union regulations (EU Directive 2010/ 63/EU). The study was revised and approved in accordance with the Ethics Committee of Alcala University, Madrid, Spain.
Arterial blood pressure was measured in conscious animals by means of a tail-cuff sphygmomanometer (LE 5001 Pressure Meter, Letica Scientific Instruments, Hospitalet, Spain) as described previously. 33 To minimize the variability of blood pressure, animals were trained for 2 days before starting the measurement to prevent stress, they were prewarmed at 30 C with a heater (LE5660/6, Letica Scientific Instruments), basal measurements were performed at the same times (11.00 h -12.00 h), and at least 20 determinations per day were recorded. One week later, blood pressure was registered in basal conditions and at 4 h and 24 h after a single i.p. dose of TWEAK (10 mg/kg body weight) or vehicle [0.2 mL phosphate-buffered saline (PBS)]. Blood pressure was also registered under the same conditions but after a single i.p. dose of FR-901533 (1 mg/kg body weight), 30, 36 an ECE-1 blocker, or BQ123 (0.5 mg/kg body weight), 37 a specific antagonist of ET A receptor. After that, animals were anesthetized with pentobarbital (50 mg/kg i.p.), and a blood sample was collected through right ventricular puncture. Plasma was separated (3500 rpm, 10 min) and stored at -80 C until ET-1 determination. Aorta and lungs were removed through a thoracic-abdominal incision and stored until analysis. Aorta and lung portions were collected in 4% para-formaldehyde for histological studies.
Slices of aorta and lung underwent immunostaining 34 with rabbit anti-ECE-1 antibody. Antibody-protein complex was detected with anti-HRPhorseradish secondary antibody using diaminobenzidine reagent. At least four sections per tissue and animal in triplicate were analysed for each immunostaining.
Preparation of the aortic rings and ex vivo measurement of vascular reactivity
After treatment of mice with a single i.p. dose of TWEAK (10 mg/kg body weight), or vehicle (0.2 mL PBS) for 4 h, aortas were extracted to prepare aortic rings. Preparations of the aortic rings to measure the tension were according to previous described methods. 38 The rings were incubated in an Automatic Organ Bath and were set at an initial resting tension of 0.5 g and tension changes were recorded with an isometric force transducer. The tissues were allowed to equilibrate for 60 min prior to experimentation and the resting tension re-adjusted to 0.5 g if required. The vessels were exposed to 80 mM KCl to verify their functional integrity. Then, the bath was washed three times before adding treatments of each aortic ring from TWEAK or control mice, which are detailed in figure legend. At the end of incubation, isometric tension of each ring with each experimental condition in duplicate was recorded.
Measurement of ET-1 levels and ECE-1 activity
Supernatants of confluent monolayer of EA cells treated for different times with 100 ng/mL TWEAK were collected, lyophilized, and stored at -70 C until assay. ET-1 levels from supernatants of cells and plasma from mice were measured in duplicate by ELISA (ET-1 ELISA) 
Membrane proteins from EA cells treated with 100 ng/mL TWEAK for different times were isolated as described, 29 then 30 mg of this homogenate was incubated with 10 nM human Big ET-1 for 4 h at 37 C in 250 mL of a reaction mixture containing 50 mM Tris-HCl buffer pH 7.0. The reaction was stopped by adding 600 mL of cold ethanol (-20 C). After centrifuging at 10 000 g for 10 min, supernatants were lyophilized. Dry residues were reconstituted with the assay buffer, and ET-1 production in each sample was measured by ET-1 ELISA. The cross-reactivity of the ELISA ET-1 antibody, as determined by the concentration giving 50% B/Bmax, was ET-1 (100), ET-2 (3.3), ET-3 (<0.1), Big-ET-1 (<0.1), and rat Big-ET-1 (0.1).
Western blot assays
Proteins were obtained from cells treated with TWEAK at different doses and times and tissues from mice by using the Lysis Buffer containing a protease inhibitor cocktail. Protein concentration was determined with BioRad protein assay kit. Proteins were separated on SDS-PAGE 6% (30 mg protein/ lane) and transferred onto nitrocellulose membranes. Membranes were blocked with 5% (w/v) non-fat dry milk in Tween Tris-buffered saline (TTBS) at room temperature and then incubated for 90 min with 10 mg/mL of the monoclonal anti-ECE-1 antibody (mAb AEC32-236) or for 2 h with 1:1000 dilution of rabbit anti-ET A or anti-ET B receptor antibodies. After being washed in TTBS, blots were incubated with 200-fold-diluted horseradish peroxidase-conjugated goat anti-mouse IgG. The immunoreactive bands were visualized with the SuperSignal West Pico detection system after 30 s of exposure to CL-Xposure films. Then blots were reblotted with a rabbit anti-actin antibody to normalize ECE-1 levels.
Similar experiments were performed in cytosolic and nuclear fractions from control and TWEAK-stimulated EA for different times. Proteins were separated on 8% SDS-PAGE and detected by immunoblot with rabbit anti-cFos, anti-c-Jun, anti-NFkB-p65, and anti-IkBa-p65. Blots were incubated O/N at 4 C with 1:750 dilution of each antibody in TTBS with 3% BSA. After being washed in TTBS, blots were incubated with 1/10 000 horseradish peroxidase-conjugated goat anti-rabbit IgG. The immunoreactive bands were visualized as described above. Then blots were reblotted with a rabbit anti-actin antibody in cytosolic extracts and rabbit anti-PARP antibody in nuclear extracts, to normalize protein levels.
In every experiment, a BlueStar-prestained protein marker was used to control the size of the protein under analysis.
Quantitative real-time polymerase chain reaction
Total cellular RNA extracted from EA cells was reverse transcribed with high capacity cDNA reverse transcription kit. 30, 39 ECE-1, prepro-endothelin-
Transient transfection experiments
To determine whether the effect of TWEAK on ECE-1 gene expression was mediated by the 5 0 -flanking region of the gene, endothelial cells were transfected using the pGL3-ECE-1 plasmid containing the complete human ECE-1 promoter or serial deletion fragments (A to G) linked to luciferase reporter gene, as described. 28, 30 EA cells were grown at 60-80% of confluence in 12-well plates and transfected for 24 h with each luciferase construct, by mixing plasmid DNA (0.1 mg/mL of luciferase reporter, 1 ng/mL of plasmid control from Renilla luciferase, pRL-SV40 vector, and 10 mg/mL of Canfast into complete DMEM). Transfection of IkBa dominant-negative vector were done using two plasmids: pCMV-IkB a , which expresses the wild-type IkBa protein, and pCMV-IkB aM , which expresses a mutated form of IkBa that does not undergo signal-induced phosphorylation and, thus, remains bound to NFkB. EA cells were transfected for 24 h by mixing 2 mg/mL plasmid DNA (pCMVIkB a or pCMV-IkB aM ) with 1 ng/mL of plasmid control from Renilla luciferase (pRL-SV40 vector) and 10 mg/mL Canfast reagent into OptiMEM I medium.
Jun was silenced in endothelial cells by transfecting a specific small RNA interference (siRNA) against JNK (siJun). TWEAK Receptor/Fn14 was silenced in endothelial cells by transfecting a siRNA against TWEAK Receptor/Fn14 (siFn14). An unspecific scrambled was used as transfection control. Transfections were performed using the Hyperfect transfection reagent for 72 h.
After transfections, cells were incubated with complete DMEM for 24 h, and then, TWEAK was added in some wells at different times using serum free DMEM. Luciferase activity was assessed in triplicate using a DualLuciferase Reporter Assay System and expressed as relative light units of each plasmid DNA per Renilla per mg protein of each well. In siRNA transfections, cells were processed for checking Jun or ECE-1 protein expression or checking Fn14 and ECE-1 mRNA expression, as described above.
Cellular localization of c-Fos, c-Jun, NF-kB-p65, and IkBa-p65 by immunofluorescence
Cells were grown on cover slips for 24 h. TWEAK was added at different times. After being washed twice, cells were fixed with 4% p-formaldehyde for 10 min at R/T, then 0.5% Triton X-100 was added for 10 min at R/T. After that, cells were blocked with 5% BSA for 1 h at R/T and then incubated for 1 h with rabbit anti-c-Fos and anti-c-Jun (1:200) or for 1 h with rabbit anti-NFkB-p65 or anti-IkBa-p65 (1:200). After being washed in PBS, cells were incubated with 200-fold diluted goat anti-rabbit IgG labelled with Alexa Fluor 488. Cover slips were mounted on prolong gold antifade reagent with DAPI to stain nuclei. Preparations were visualized in confocal microscope TCS-SP5.
Electrophoretic mobility shift assays
Nuclear extracts from EA treated with TWEAK at different times and electrophoretic mobility shift assays (EMSA) were displayed to check on the activation of AP-1 and NFkB, as previously described. 28, 33 To detect DNA-protein interactions, we used the LightShift Chemiluminescent EMSA Kit. Oligonucleotide sequences were based on the putative AP-1 and NFkB binding elements in the ECE-1 promoter. 40 Biotin end-labelled DNAs containing the binding site of interest (AP-1 or NFkB from ECE-1) were briefly incubated with 1 mg/mL nuclear extracts. Protein-DNA complexes were subjected to gel electrophoresis on a native polyacrylamide gel in 0.5x Tris Buffer EDTA and then transferred to a positively charged nylon membrane. The biotin end-labelled DNA was detected using the StreptavidinHorseradish Peroxidase Conjugate and the Chemiluminescent Substrate. For competition experiments, 200-fold molar excess of competitor DNA (AP-1 or NFkB oligonucleotides) was coincubated with biotin end-labelled DNAs (biotin-AP-1 or biotin-NFkB). To analyse the specificity of DNA-protein complex, 200-fold molar excess of rabbit polyclonal IgG antibodies for anti-c-Jun and anti-c-Fos, or anti-NFkB p65 were coincubated with the biotin-AP-1 or biotinNFkB, respectively.
Statistical analysis
GraphPad Prism 5 Software was used for statistical analysis. Statistical test employed are described in figure legends. Unless otherwise specified, data are expressed as the means ± SEM. The level of statistically significance was defined as P < 0.05.
Results

The effect of TWEAK on the regulation of the endothelin system
The effect of TWEAK on the regulation of the endothelin system was assessed in human endothelial cells. TWEAK induced a time-dependent TWEAK up-regulates endothelin-converting enzyme-1 rise in ET-1 production in cell supernatants ( Figure 1A) , without changing the preproET-1 mRNA expression ( Figure 1B) . ECE-1 protein content increased after cell incubation with TWEAK, in a dose-( Figure 1C ) and time-dependent way ( Figure 1D ), reaching the maximum effect at 6-8 h with a dose of 100 ng/mL. Changes in the protein content were confirmed by directly measuring ECE-1 activity in membrane extracts that also increased time-dependently after TWEAK treatment ( Figure 1E ). This treatment also induced a progressive increase of ECE-1 mRNA expression, reaching a peak at 4 h ( Figure 2A) . The TWEAK-dependent increase in ET-1 synthesis was blocked by CGS-35066, an ECE-1 inhibitor 35 ( Figure 1F) . No changes were observed in the cellular content of the ET B receptor in the presence of TWEAK ( Figure 1G ), but this cytokine induced a significant time-dependent increase on the endothelial content of the ET A receptor ( Figure 1H ).
Mechanism involved in TWEAKinduced ECE-1 expression
To analyse the mechanisms involved in the ECE-1 regulation by TWEAK, experiments combining the analysis of promoter activity and the study of the regulation of transcription factors were performed. TWEAK increased the promoter activity of ECE-1 ( Figure 2B ), suggesting a transcriptional modulation. For the analysis of the transcription factors that could be involved in this promoter activity up-regulation, similar experiments were performed using serial deletions of the promoter. The results are shown in Figure 2C . The TWEAK-dependent stimulation on ECE-1 promoter activity was partially blocked when cells were transfected with the construct A (deletion between -650 and -682 bp) ( Figure  2C ) and totally blocked when cells were transfected with the construct B (deletion between -596 and -682 bp) ( Figure 2C) . No additional differences in the luciferase activity were observed between control and TWEAK-treated transfected cells with the constructs C to G, suggesting that TWEAK affected only the regulation of any potential factor removed in constructs A and B.
The best recognized response elements in the promoter region deleted in the first (A) and second (B) constructs of ECE-1 were AP-1 and NF-jB binding sites, respectively. Thus, we tested AP-1 and NF-kB activations by TWEAK. First, AP-1 activation was assessed by two means: c-Fos and c-Jun immunofluorescence ( Figure 3A) and Western blot ( Figure 3B) . A rapid and transient nuclear accumulation of both proteins was observed after 15-30 min of treatment with TWEAK. Second, the binding of the transcription factor AP-1 to the nuclei of cells stimulated with TWEAK was tested by EMSA. A rapid increase of the Biotinlabelled AP-1 binding was observed ( Figure 3C ). This effect was specific for AP-1 because the signal disappeared with 200-fold excess of unlabelled AP-1 oligonucleotide (lanes 3 and 7, bottom of Figure 3C ), remained almost unchanged with 200-fold excess of unlabelled NF-jB oligonucleotide (lane 4, bottom of Figure 3C ) and was super shifted with antibodies c-Jun and c-Fos (lane 8, bottom of Figure 3C ).
After that, we studied the relevance of AP-1 activation on TWEAKdependent ECE-1 activation. For this purpose, some experiments with pharmacological inhibitors were performed. PD-98059, which inhibits phosphorylation of ERK 1 =2 by MEK and subsequently c-Fos, and SP-600125, which inhibits JNK and prevents c-Jun activation, were selected at maximal inhibiting doses previously tested. 41 The presence of SP-600125 and PD-98059 only partially reverted the effect of TWEAK on ECE-1 promoter activity ( Figure 4A ) and on ECE-1 protein expression ( Figure 4B ). In addition, JNK was silenced with a specific small interference RNA against JNK (siJun), and ECE-1 protein expression was tested in the presence or not of TWEAK. When JNK was silenced, ECE-1 protein expression was partially blocked in response to TWEAK, compared with control conditions ( Figure 4C ), suggesting that other transcription factors are implied in TWEAK-induced ECE-1 effect, in addition to AP-1. Therefore, NF-jB activation was also tested. The intracellular localization of NF-jB-p65 and IjB-p65 after cell incubation with TWEAK was studied by immunofluorescence ( Figure 5A ) and Western blot ( Figure  5B) . A rapid and transient nuclear accumulation of NF-jB-p65 was found after 60 min of treatment with TWEAK. The binding of the transcription factor NF-jB to the nuclei of cells stimulated with TWEAK was tested by EMSA. A rapid increase of the Biotin-labelled NF-jB binding was observed ( Figure 5 ). This effect was specific for NF-jB because the signal disappeared with 200-fold excess of unlabelled NF-jB oligonucleotide (lane 3, bottom of Figure 5C ), remained almost unchanged with 200-fold excess of unlabelled AP-1 oligonucleotide (lane 4, bottom of Figure 5C ), and was super shifted with NF-jB-p65 antibody (lane 5, bottom of Figure 5C ).
As we previously performed for AP-1, we also assessed the relevance of NF-jB activation on TWEAK-dependent ECE-1 activation. For this purpose, cells were incubated with TWEAK in the presence of a potent inhibitor of NF-kB activation such as PDTC (pyrrolidine dithiocarbamate). PDTC partially but significantly blocked the rise induced by TWEAK on ECE-1 promoter activity ( Figure 6A ) as well as on ECE-1 protein content ( Figure 6B ). In addition, experiments with a IjBa dominantnegative vector were done by transfecting cells with two plasmids, pCMV-IjBa, which expresses the wild-type IjBa protein, and pCMVIjBaM, which expresses a mutated form of IjBa that does not undergo signal-induced phosphorylation, and thus, remains bound to NF-jB. Figure 6C shows TWEAK was unable to induce ECE-1 protein expression when cells expressed a mutated IjBa form. These results suggest that ECE-1 up-regulation induced by TWEAK partially depends on the activation of both transcription factors NF-jB and AP-1.
To test the specificity of TWEAK on ECE-1 effect in endothelial cells, TWEAK Receptor/Fn14 was silenced by transfecting cells with a specific small interference RNA against Fn14 (siFn14). Under these conditions, Fn14 cellular content was reduced by about 60% (Scrambled transfection: Control 100%; TWEAK 95 ± 11%. siFn14 transfection: Control 43 ± 8%; TWEAK 30 ± 12%). Treatment with TWEAK in transfected cells with siFn14 did not induce any increase on ECE-1 protein content compared with control cells (ECE-1 expression data: Scrambled transfection: Control 100%; TWEAK 150*±9%. siFn14 transfection: Control 100%; TWEAK 108 ± 10%), (n ¼ 6, *P < 0.05 vs. other groups).
In vivo effects of TWEAK on mice
To test the relevance of these in vitro findings, the effect of TWEAK was tested in normal mice treated with a single i.p. injection of the drug for 24 h. A significant but transient increase of blood pressure was observed after the injection of 10 mg/kg body weight of TWEAK, with a change of 27 mmHg in the systolic blood pressure (SBP) at 4 h and an almost normal blood pressure at 24 h ( Figure 7A) . Changes in plasma ET-1 levels paralleled the changes in blood pressure, with a maximum at 4 h and a slight but significant increase at 24 h ( Figure 7A) . The TWEAK-induced changes in blood pressure were not observed when mice were pretreated with an antagonist of ECE-1, FR-901533, or a specific antagonist of ET A receptor, BQ123 ( Figure 7A ). In addition, increasing doses of TWEAK were tested in mice for 4 h, finding a significant increasing SBP in a dose-response way ( Figure 7A) . The analysis by Western blot of the lungs and aortas of these animals after treating them with two doses of TWEAK for 4 h or with TWEAK 10 mg/kg body weight for 4 and 24 h Values are the mean ± SEM of six independent experiments, *P < 0.05 vs. control cells (C) (panels A and B); and they are expressed as fold induction between TW and control cells, *P < 0.05 vs. ECE-1 and **P < 0.05 vs. ECE-1 and deletion A (panel C). Statistical test applied was one-way analysis of variance (ANOVA) with repeated measures, followed by Dunnett s multiple comparison test (panels A and B) or followed by Bonferroni multiple comparison test (panel C). showed an increased ECE-1 protein content not only at 4 h but also at 24 h ( Figure 7B and see Supplementary material online, Figure S1 ). A rise in ECE-1 expression at 24 h was also confirmed by immunohistochemistry ( Figure 7C) . According to the staining, an increased ECE content was observed in the different vascular layers, but it was particularly relevant at endothelial level.
To accumulate more evidence concerning the in vivo ECE-1 up-regulation by TWEAK, aorta rings were isolated from wild type and TWEAK- with 50 mM PD-98059 (PD, ERK1/2 inhibitor) or with 25 mM SP-600125 (SP, JNK inhibitor) and then incubated for 6 h with 100 ng/mL TW. Then, ECE-1 promoter activity (A) and ECE-1 protein content (B) were analysed. Values are the mean ± SEM of six independent experiments, *P < 0.05 vs. C, and **P < 0.05 vs. TW. (C) Cells were transfected with a small-interfering JNK RNA (siJun) or control (scrambled) for 72 h, and then cells were treated with 100 ng/mL TW for 6 h. Protein levels of ECE-1, and c-Jun were analysed. A representative Western blot is shown at the top, whereas the densitometric analysis is given below. Values are the mean ± SEM of six independent experiments, *P < 0.05 vs. basal conditions transfected with scrambled (C), and **P < 0.05 vs. both TW. Statistical test applied was one-way analysis of variance (ANOVA) with repeated measures, followed by Bonferroni multiple comparison test. with 100 mM PDTC, an NFkB inhibitor, and then incubated with 100 ng/mL TW for 6 h. Then, ECE-1 promoter activity (A) and ECE-1 protein content (B) were analysed. Values are the mean ± SEM of six independent experiments, *P < 0.05 vs. C, and **P < 0.05 vs. TW. (C) Cells were transfected with plasmids containing a wild-type IkB (pCMV-IKBa), or with a mutant IkBa (pCMV-IkBaM), which avoid nuclear translocation of NFkB. After incubating cells with 100 ng/mL TW for 6 h, ECE-1 protein content was studied by Western blot. Values are the mean ± SEM of six independent experiments, *P < 0.05 vs. control cells (C) of each transfection, and **P < 0.05 vs. different TW. Statistical test applied was one-way analysis of variance (ANOVA) with repeated measures, followed by Bonferroni multiple comparison test. treated mice for 4 h, and vascular reactivity was assessed in the presence of the substrate for ET-1 synthesis, Big ET-1. Big ET-1 induced an increased contraction in the rings from TWEAK-treated mice compared with control mice ( Figure 7D ) that exhibited a dose-response pattern (see Supplementary material online, Figure S2A ) and that was higher using 200 nM Big ET-1 (see Supplementary material online, Figure S2A ). That effect disappeared in the presence of CGS-35066 (a selective ECE-1 antagonist) or Bosentan (a dual ET A/B receptor antagonist) ( Figure 7D) . The contractile response to angiotensin II did not differ between the control and the TWEAK-treated animals ( Figure 7D ), but the relaxing response to sodium nitroprusside (SNP) ( Figure 7E ) was less pronounced in the aortic rings from TWEAK-treated animals.
Discussion
Present results have for the first time demonstrated that TWEAK may stimulate ET-1 synthesis, through the up-regulation of ECE-1. This upregulation seems to be dependent on the transcriptional regulation of the ECE-1 gene, through the modulation of AP-1 and NF-kB transcription factors. As a consequence of this modulation, mice treated with a single i.p. dose of TWEAK exhibit a transient increase in blood pressure. TWEAK is a rather recently discovered cytokine, which has been increasingly studied in the last years. Its role in different pathological processes such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, renal injury, stroke, neuroinflammation, and neurodegeneration, or even in several types of cancer has started to be defined. [5] [6] [7] [8] Moreover, taking into account that inflammation and vascular damage are closely related phenomena, the possibility that this cytokine could also be involved in the pathogenesis of arteriosclerosis has also been considered. In this sense, it has been described that TWEAK modulates endothelial cell function, inducing proliferation, [14] [15] [16] angiogenesis, 16 and secretion of different chemokines, 15 it also seems it plays a role in the inflammatory response that takes place in atherosclerotic lesions, and some authors suggest that circulating TWEAK levels could constitute a marker of vascular damage. Indirect evidence suggests that TWEAK could contribute to the genesis of atherosclerosis in inflammatory or metabolic diseases, through the increased endothelin synthesis. Thus, atherosclerosis of ApoE mice got worse by TWEAK treatment. 17 Moreover, some inflammatory diseases as systemic lupus erythematosus are characterized by increased TWEAK 42 and endothelin levels, 43, 44 as well as a high prevalence of hypertension or atherosclerosis. [44] [45] [46] [47] Regarding the possible vascular effects of TWEAK, no previous studies have tested the possibility that this cytokine could modulate the synthesis of endothelial vasoactive factors, with the subsequent effects on vascular wall physiology or even on the regulation of tissular flow. As previously stated, this is the first description of the ability of TWEAK to stimulate ET-1 synthesis, through the up-regulation of ECE-1. Different results support this contention. In cultured endothelial cells, TWEAK induced an increased release of ET-1 to the incubation media, associated to an augmented ECE-1 content and activity in cells, without changing prepro-ET-1 expression. The TWEAK-dependent rise in ET-1 production seems to be specific of ECE-1 because it was completely blocked by a specific inhibitor of ECE-1 activity. Similar findings were obtained by using an in vivo experimental approach. In mice treated with a single TWEAK injection, an increased ECE-1 protein expression was observed in lungs and aorta, as well as a significant rise in plasma ET-1 levels, after 4 h and 24 h of treatment. Only scarce reports trying to relate ET-1 to TWEAK have been previously performed. Novoyatleva et al. 13 suggested that Fn14 expression is regulated by ET-1 in cardiac fibroblast, and some authors have reported the relationship between inflammatory responses and higher ET-1, ECE-1, and TNF-alpha production. 13, 48 The ability of TWEAK for modulation endothelial vasoactive factors could go beyond the increased synthesis of ET-1. In fact, TWEAK also increases the expression of ET A receptor in endothelial cells, with the subsequent possible modulation of NO system. 37 Experiments devoted to the analysis of the ability of TWEAK for regulating this NO system must be performed. The pathophysiological consequences of the TWEAK-dependent increased ET-1 synthesis may be very relevant, as this autacoid exerts different actions not only as a vasoactive peptide but also as a regulator of cell proliferation, fibrosis or inflammation. Nevertheless, present studies were devoted to test the haemodynamic consequences of TWEAK administration in animals. TWEAK induced a slight but significant increase in blood pressure after 4 h of treatment, which disappeared at 24 h, and which could be prevented not only by FR-901533, a specific ECE-1 inhibitor, but also by BQ123, a specific inhibitor of ET A receptor. Changes in blood pressure were paralleled by changes in ET-1 plasma concentrations and changes in ECE-1 protein content in aorta and lungs. Moreover, aortic rings from TWEAK-treated mice showed higher contractile activity in the presence of Big ET-1 than aortic rings from wild type mice, an effect that was completely inhibited by CGS-35066, a specific inhibitor of ECE-1 activity, and by bosentan, a dual inhibitor of endothelin receptors. These findings strongly support the pathophysiological relevance of the changes observed in ECE-1 protein content, as not only quantitative differences in the protein were observed but also functional changes specifically dependent on it were demonstrated.
An interesting consequence of the present findings could be related to the treatment of hypertensive conditions in patients with inflammatory diseases. Some forms of pulmonary hypertension develop in a context of inflammatory damage, and bosentan, a dual endothelin receptor blocker has been proved to be useful in some of these patients. It could be proposed that the inflammation-dependent increased TWEAK synthesis, with the subsequent ET-1 overproduction, could play a role in the genesis of the haemodynamic changes at the lung. This hypothesis has not been previously proven, but some reports suggest a relationship Tension was also registered after 30 min of adding 1 mM Angiotensin II (AII). Results are expressed as the increment in tension (registered in grams) over the basal conditions. Values are the mean ± SEM of 10 mice, *P < 0.05 vs. control (C); **P < 0.05 vs. vehicle, and statistical test applied was two-way RM ANOVA followed by Bonferroni post-test. (E) Aortas were extracted from mice after 4 h to prepare aortic rings. Aortic rings from TW (closed triangles) or vehicle (closed squares) were treated with norepinephrine (NE) to contract aortic rings (maximal contraction: 100%), and then their relaxations were studied by adding increasing concentrations of SNP, and tension was registered to calculate percentage of relaxation. Values are the mean ± SEM of 10 mice, and statistical test applied was two-way RM ANOVA followed by Bonferroni post-test.
between circulating TWEAK levels and pulmonary hypertension. 49 Concerning systemic hypertension in inflammatory diseases, no previous reports support a potential role of a TWEAK-induced ET-1 synthesis increase in the development of hypertension. However, considering the present results and the fact that TWEAK may be increased in some autoimmune diseases, 50 it could be hypothesized that ET-1 would play a significant role in the maintenance of high blood pressure in these patients and endothelin blockers would be especially adequate for the treatment of this condition. Although the use of these blockers has not been adequately defined in the field of the treatment of systemic hypertension, increasing evidence supports the role of ET-1 in this process, 51, 52 and ET A receptor blockers lower blood pressure in experimental models of hypertension. 53 Part of the results included in this manuscript concern the mechanisms responsible for the TWEAK-dependent ECE-1 up-regulation. Our findings support a transcriptional regulatory mechanism, as TWEAK induced the ECE-1 promoter activity, with the subsequently increased ECE-1 mRNA content. Two transcription factors seem to be involved in this regulation: AP-1 and NF-kB, as (i) both factors were activated by TWEAK in our cells and (ii) the increased ECE-1 promoter activity and/ or protein content observed in the presence of cytokine were abolished by the deletion of the elements responsive to these factors in the ECE-1 promoter or by pharmacological blockers. Additionally, our results demonstrate that the effect of TWEAK on ECE-1 was dependent on the classically described cellular effect of TWEAK, as it disappeared when silencing the TWEAK receptor Fn14 in endothelial cells.
In summary (Figure 8 ), present data demonstrate that TWEAK modulates ET-1 synthesis in endothelial cells through the up-regulation of ECE-1. Fn14 and both AP-1 and NF-kB are involved in the genesis of this effect. This mechanism may contribute to explain the potential cardiovascular effects of the cytokine, and it may constitute an additional link between inflammation and arteriosclerosis. tivates the transcription factors AP-1 and NF-kB. Both transcription factors induce transcription of ECE-1, increasing amount of ECE-1 protein and then ET-1 production. ET-1 is responsible of the rise in blood pressure observed in TWEAK-treated mice. All antagonists, inhibitors, and small interference RNAs used are highlighted in orange. TWEAK through Fn14 is able to activate different pathways such as MAPK or TAKs, which induce transcription factors such as AP-1 and NF-kB. Both transcription factors in our study induce transcription of ECE-1, increasing amount of ECE-1 protein and then ET-1 production. ET-1 is responsible of the rise in blood pressure observed in TWEAK-treated mice. All antagonists, inhibitors, and small interference RNAs used are highlighted in orange. TRAF, TNF receptor-associated factor; cIPA1, cellular inhibitor of apoptosis protein 1; TAK, transforming growth factor-ß activated kinase; IKK, I kappa B kinase; MAPK, mitogen-activated protein kinase; JNKs, c-Jun N-terminal kinase; ECE-1, endothelin-converting-enzyme-1; Big ET-1, ET-1 substrate; ET-1, endothelin-1; GCS-35066 and FR-901533, specific ECE-1 activity inhibitors; BQ123, an ET A receptor antagonist; PD-98059, an ERK1/2 inhibitor; SP-600125, a JNK inhibitor; siJun, small interference against JNK; siFn14, small interference against Fn14; pCMV-IkBaM, plasmid containing a mutant IkBa which avoid translocation of NFkB; PDTC, inhibitor of NFkB activation.
TWEAK up-regulates endothelin-converting enzyme-1
